Loading
5 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Fit | Higher-risk, fit for transplant | Allogeneic stem cell transplant, usually under 70 and at MIPSS70 high or DIPSS intermediate-2 or higher, after JAK inhibitor to reduce spleen size. | NCCN Guidelines: Myeloproliferative Neoplasms | 92 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Lower-risk, asymptomatic | Observation; aspirin for thrombosis risk where platelets are high; hydroxyurea or interferon for proliferative features. | NCCN Guidelines: Myeloproliferative Neoplasms | 76 | |
| All comers | Symptomatic splenomegaly or constitutional symptoms | Ruxolitinib (COMFORT-I and II) first; fedratinib after ruxolitinib failure or intolerance; pacritinib if platelets are below 50 x 10^9/L; momelotinib if anaemic. | NCCN Guidelines: Myeloproliferative Neoplasms | 87 | |
| All comers | Anaemia of myelofibrosis | Momelotinib (MOMENTUM), erythropoiesis-stimulating agents where erythropoietin is low, danazol, transfusion with iron chelation; luspatercept in trials (INDEPENDENCE). | MomelotinibEpoetin alfaTransfusion support and anaemia managementLuspaterceptAn Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on ConcomiStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | NCCN Guidelines: Myeloproliferative Neoplasms | 90 |
| All comers | Ruxolitinib failure and trials | Switch JAK inhibitor; combination trials of ruxolitinib with navitoclax, pelabresib, selinexor or imetelstat; imetelstat versus best available therapy in IMpactMF. | NavitoclaxPelabresibSelinexorImetelstatStudy of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisStudy of Selinexor in Combination With Ruxolitinib in MyelofibrosisIMpactMFExtended Access of Momelotinib in Adults With Myelofibrosis | 71 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.